Breast cancer.

Research output: Contribution to journalArticle

Abstract

Several issues of clinical importance were in the forefront of discussion during 1989. Heated debates continue regarding whether alcohol, oral contraceptives or hormonal replacement therapy modifies a patient's risk for developing breast cancer. It is quite apparent, and rightfully so, that a major impetus in the arena of research in breast cancer seems to be towards cure of the disease. The rationale for offering adjuvant systemic treatment to a larger group of primary breast cancer patients who have a potential for cure certainly seems justifiable. However, one still needs to individualize patients based on their prognosis and objectively weigh the potential benefits and risks of adjuvant therapy in a given clinical situation, especially in patients with less than 1 cm primary tumors and negative axillary nodes as they have been shown to have a 20-year recurrence-free survival of 86%. A better understanding of several molecular and genetic parameters has begun. Further developments in this area may lead to clinically appropriate means of preventing or treating this disease. Metastatic disease continues to remain an incurable entity. Efforts aimed at treating metastatic disease with more 'intensive dose chemotherapy' have not been demonstrated to be beneficial for affected patients.

Original languageEnglish (US)
Pages (from-to)571-589
Number of pages19
JournalCancer chemotherapy and biological response modifiers
Volume12
StatePublished - 1991

Fingerprint

Breast Neoplasms
Contraceptives, Oral, Hormonal
Molecular Biology
Therapeutics
Alcohols
Recurrence
Drug Therapy
Survival
Research
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Breast cancer. / Patel, S. R.; Loprinzi, Charles Lawrence.

In: Cancer chemotherapy and biological response modifiers, Vol. 12, 1991, p. 571-589.

Research output: Contribution to journalArticle

@article{450d9e108aa0439d83562e66481647ae,
title = "Breast cancer.",
abstract = "Several issues of clinical importance were in the forefront of discussion during 1989. Heated debates continue regarding whether alcohol, oral contraceptives or hormonal replacement therapy modifies a patient's risk for developing breast cancer. It is quite apparent, and rightfully so, that a major impetus in the arena of research in breast cancer seems to be towards cure of the disease. The rationale for offering adjuvant systemic treatment to a larger group of primary breast cancer patients who have a potential for cure certainly seems justifiable. However, one still needs to individualize patients based on their prognosis and objectively weigh the potential benefits and risks of adjuvant therapy in a given clinical situation, especially in patients with less than 1 cm primary tumors and negative axillary nodes as they have been shown to have a 20-year recurrence-free survival of 86{\%}. A better understanding of several molecular and genetic parameters has begun. Further developments in this area may lead to clinically appropriate means of preventing or treating this disease. Metastatic disease continues to remain an incurable entity. Efforts aimed at treating metastatic disease with more 'intensive dose chemotherapy' have not been demonstrated to be beneficial for affected patients.",
author = "Patel, {S. R.} and Loprinzi, {Charles Lawrence}",
year = "1991",
language = "English (US)",
volume = "12",
pages = "571--589",
journal = "Cancer chemotherapy and biological response modifiers",
issn = "0921-4410",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Breast cancer.

AU - Patel, S. R.

AU - Loprinzi, Charles Lawrence

PY - 1991

Y1 - 1991

N2 - Several issues of clinical importance were in the forefront of discussion during 1989. Heated debates continue regarding whether alcohol, oral contraceptives or hormonal replacement therapy modifies a patient's risk for developing breast cancer. It is quite apparent, and rightfully so, that a major impetus in the arena of research in breast cancer seems to be towards cure of the disease. The rationale for offering adjuvant systemic treatment to a larger group of primary breast cancer patients who have a potential for cure certainly seems justifiable. However, one still needs to individualize patients based on their prognosis and objectively weigh the potential benefits and risks of adjuvant therapy in a given clinical situation, especially in patients with less than 1 cm primary tumors and negative axillary nodes as they have been shown to have a 20-year recurrence-free survival of 86%. A better understanding of several molecular and genetic parameters has begun. Further developments in this area may lead to clinically appropriate means of preventing or treating this disease. Metastatic disease continues to remain an incurable entity. Efforts aimed at treating metastatic disease with more 'intensive dose chemotherapy' have not been demonstrated to be beneficial for affected patients.

AB - Several issues of clinical importance were in the forefront of discussion during 1989. Heated debates continue regarding whether alcohol, oral contraceptives or hormonal replacement therapy modifies a patient's risk for developing breast cancer. It is quite apparent, and rightfully so, that a major impetus in the arena of research in breast cancer seems to be towards cure of the disease. The rationale for offering adjuvant systemic treatment to a larger group of primary breast cancer patients who have a potential for cure certainly seems justifiable. However, one still needs to individualize patients based on their prognosis and objectively weigh the potential benefits and risks of adjuvant therapy in a given clinical situation, especially in patients with less than 1 cm primary tumors and negative axillary nodes as they have been shown to have a 20-year recurrence-free survival of 86%. A better understanding of several molecular and genetic parameters has begun. Further developments in this area may lead to clinically appropriate means of preventing or treating this disease. Metastatic disease continues to remain an incurable entity. Efforts aimed at treating metastatic disease with more 'intensive dose chemotherapy' have not been demonstrated to be beneficial for affected patients.

UR - http://www.scopus.com/inward/record.url?scp=0026054698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026054698&partnerID=8YFLogxK

M3 - Article

C2 - 1931456

AN - SCOPUS:0026054698

VL - 12

SP - 571

EP - 589

JO - Cancer chemotherapy and biological response modifiers

JF - Cancer chemotherapy and biological response modifiers

SN - 0921-4410

ER -